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Abstract
Background: The aim of this study was to develop and psychometrically test a short, patient-
reported questionnaire to be used in clinical practice for patients with Irritable Bowel Syndrome
(IBS). The Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) questionnaire was
designed to measure the treatment response of symptoms and well-being in patients suffering from
IBS.
Methods:  The VAS-IBS was psychometrically tested for content and criterion validity, scale
acceptability, item-reduction, internal reliability consistency, simplicity, and speed. Two samples
were used. One expert panel (five physicians and four registered nurses), who gave their opinion
on the content validity, and one of 71 patients with IBS (mean age 38 years SD +13, range 19–65),
who completed the VAS-IBS, as well as the Gastrointestinal Symptom Rating Scale and the
Psychological General Well-Being Index for criterion validity.
Results: The items in the VAS-IBS capture the main physical concerns women with IBS might
present and the psychometric testing confirmed that the VAS-IBS is an acceptable homogeneous
patient-reported questionnaire indicated by Cronbach's alpha internal consistency reliability
coefficient, with a value of 0.85. All correlations to test the criterion validity performed by using
Pearson's correlation test, were statistically significant (p < 0.0001) and in the expected directions.
The VAS-IBS is easy to complete and unproblematic to calculate.
Conclusion: The VAS-IBS appears to be reliable and user-friendly, for patients as well as for health
professionals. The final version of the VAS-IBS including nine items needs to be further tested in
clinical practice cross-culturally in women as well as in men.
Background
Irritable Bowel Syndrome (IBS) is a common, global,
functional, gastrointestinal disorder, affecting a signifi-
cant number of people, predominantly women [1,2]. Eti-
ology and pathophysiology is insufficiently understood,
but it is generally accepted that the symptoms of IBS are
multidetermined, and can be explained as a biopsychoso-
cial model [3]. Early life factors can later in life influence
the patient's psychosocial experience and physiological
function, and generate gastrointestinal symptoms in a vul-
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nerable patient. The inter-relationship between the
patient's psychosocial status and physiology will affect
how the patient experiences the symptoms, the patient's
reaction, as well as the clinical outcome [3]. IBS has tradi-
tionally been considered as a diagnosis of exclusion rather
than a primary diagnosis, since there are no observable
biochemical and/or structural abnormalities to be found
[4,5]. The diagnosis IBS is based on the Rome criteria and
a third version has been presented during spring 2006
[3,6] (Table 1). Abdominal pain and bloating are the
dominant symptoms of IBS [7-9], and also the most trou-
blesome [8,10].
It is difficult in clinical practice to estimate the sympto-
matic changes occurring in patients having IBS based on
to their description, as well as comparing the effect of dif-
ferent treatments. There is a need to translate the patients'
perception of their symptoms and their subjective well-
being into numbers. A patient-reported, short (less than
10 items) and reliable measuring questionnaire could be
of help. It is important that the questionnaire is straight-
forward to calculate and easy to understand for patients as
well as for health professionals, to maintain a high adher-
ence from both groups. This questionnaire should serve as
a complement to the anamnesis and measure the
response to treatment of symptoms related to IBS as well
as the general well-being of the patient. A search in
Medline and Cinahl in 2001 did not show the existence of
a questionnaire that fulfilled these criteria. The identified
questionnaires showed reasonable psychometric and
methodological qualities [11-13], but not one of the ques-
tionnaires identified is optimal in all aspects [13]. The
identified questionnaires have too many (more than 10)
or inadequate questions (often only focus on pain) to
assess outcomes of interventions in daily clinical practise,
and are therefore not suitable to be used.
The aim of this study was therefore to develop and psy-
chometrically test a short, patient-reported questionnaire
to be used in clinical practice by different health care pro-
fessionals to assess the status over time for patients with
established IBS.
Methods
The development of the Visual Analogue Scale for Irritable 
Bowel Syndrome (VAS-IBS)
Creating suitable items
Items to be used in a questionnaire can be generated from
the literature [14,15], and to get a conceptualization of the
construct of interest a literature review of symptoms and
inconveniences experienced by patients with IBS was per-
formed. The most outstanding physical symptoms identi-
fied were divided into six main groups; Abdominal Pain,
Diarrhoea, Constipation, Bloating and Flatulence, Abnormal
bowel passage and  Vomiting and Nausea. All symptoms
except Vomiting and Nausea also support the diagnosis of
IBS. Symptoms included in the group Abnormal bowel pas-
sage (straining, urgency or feeling of incomplete evacua-
tion) might also be connected to diarrhoea, to
constipation as well as to the use of laxatives [16] and
these inconveniences have been reported by patients as
minor problems [7]. Since it might be difficult to evaluate
symptoms associated with Abnormal bowel passage on a
scale, and the VAS-IBS should serve as a complement to
the anamnesis, it may be preferable to discuss these symp-
toms. One item for each physical symptom was created;
Abdominal Pain, Diarrhoea, Constipation, Bloating and Flat-
ulence, and Vomiting and Nausea. An overall item concern-
Table 1: The criteria for the diagnosis Irritable Bowel Syndrome according to the Rome II and III consensus
Rome II: At least 12 weeks, which need not be consecutive, in the preceding 12 months, of abdominal discomfort or pain that has two of three 
features:
Rome III: At least 3 months, with onset at least 6 months previously of recurrent abdominal pain or discomfort associated with 2 or more of the 
following:
(1) Relieved with defecation; and/or
(2) Onset associated with a change in frequency of stool; and/or
(3) Onset associated with a change in form (appearance) of stool.
Supportive symptoms:
1. Fewer than 3 bowel movements a week
2. More than 3 bowel movements a day
3. Hard or lumpy stools
4. Loose (mushy) or watery stools
5. Straining during a bowel movement
6. Urgency (having to rush to have a bowel movement)
7. Feeling of incomplete bowel movement
8. Passing mucus (white material) during a bowel movement
9. Abdominal fullness, bloating or swelling
(Rome II: Thompson et al. 1999; p1144, Rome III: Chang 2006).BMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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ing the patient's bowel symptoms was also included in the
questionnaire, and the intension was to use it as a control
item for psychometric testing. This item was supposed to
be removed in the final version of the VAS-IBS.
Besides physical health problems, IBS also has a negative
influence on a person's mental health [17,18] as well as
on his/hers daily life [19,20], and therefore questions
related to these subjects were added. However, the focus
of the questionnaire should still be on the patient's phys-
ical symptoms. Totally three items were created. One item
related to mental health and two items related to daily life
to see which of them best corresponded to the intention
of the questionnaire. It is a common approach to have a
number of items addressing a single underlying character-
istic, and to use only one, all-inclusive, self-administered,
single, global and item-specific question of each concept
may appear to be insufficient. However, a single question
may well provide information on all aspects of a phenom-
enon, and a summary of an individual's perception [21].
The time window was set to during the previous week, since
that is the same time window as for the Gastrointestinal
Symptom Rating Scale (GSRS) and the Psychological Gen-
eral Well-Being Index (PGWB), which were chosen as
comparable questionnaires to test the criterion validity of
the VAS-IBS.
The method of the scale
The purpose of the VAS-IBS was to form a clinical an opin-
ion of each of the patient's health related complaints over
time, and not to calculate a final score. The visual ana-
logue scale (VAS) was chosen for each of the items. The
method of VAS has earlier been used to measure well-
being and symptoms in patients with IBS [22-25]. The
VAS is preferable to graded scales, since the steps between
the descriptive terms are not known [26]. If a graded scale
contains words, one can not be sure that the true feeling
of the respondent has been captured, since a respondent's
view of the meaning of a word may not correspond to the
researcher's view [27]. Visual analogue scale can be used
regardless of language [28], which is an advantage since
health professionals meet patients in clinical practice
from different cultures. The VAS has been shown to be a
reliable scale with results easily calculated [26,29,30].
However, a change of one point or more on a 7-point Lik-
ert scale might be easier to pinpoint for the health profes-
sionals, than a change of 10-points on a VAS [29]. On the
other hand, the patient has more of a choice on a VAS. In
the VAS-IBS the patients were supposed to record the over-
all severity of each item on a 100 millimetre long line
(very severe discomfort = 0 to no discomfort at all = 100)
[15]. Horizontal lines seem to be preferred to vertical lines
[31]. Graduation, verbal or numerical labels were not
placed along the line, as there was a risk that there might
be a clustering of responses beside the labels [30], and
thereby make the results more difficult to judge.
Samples
Two separate samples were used, one expert panel as well
as patients suffering from IBS. The members of the expert
panel were chosen by the author and a physician. The
panel consisted of doctors and nurses who meet patients
with IBS in daily clinical practice, two professors and three
physicians all specialized in gastroenterology, and five
registered nurses. Their assignment was to give their opin-
ion on the content validity of the VAS-IBS by the use of a
content validity index [32]. The questionnaire, together
with an information letter was mailed to the members of
the expert panel in November 2004. A reminder was sent
out to a non-responding member (a registered nurse), but
there was no reply. In all, the responses of nine members
were analyzed.
To identify suitable patients who had visited a gastroen-
terology clinic for long and short time as well as only a pri-
mary care centre, an enquiry was made among patients
who had visited a gastroenterology university clinic in
Sweden, between 1 January 1998 and 20 November 2005
and among those who had been referred for a second
opinion to the same clinic between 15 May 2003 and 15
May 2004. The referred patients were recruited before they
visited any health care professional working at the hospi-
tal. Patients with severe diseases, for example liver or kid-
ney diseases, chronic pulmonary or heart diseases, were
excluded. Only patients with IBS with symptoms present
in the previous month were qualified to participate. No
more than five men were identified and they were not
included, since they were few and there are differences
between women and men concerning symptoms related
to IBS [10,33]. Extra intestinal symptoms such as head-
ache and other chronic pain are also more common in
women [34] and they report a lower Health-Related Qual-
ity of Life [10,35,36].
In total, 181 female patients who fulfilled the Rome II cri-
teria for IBS [37] verified by the patients' medical record,
were identified and invited to participate in research, but
110 did not want to participate in any offered study. Sixty-
eight women did not reply to our request, and the reasons
the other 42 women gave for refraining were "not inter-
ested" (n = 25), "no symptoms at the moment" (n = 6),
they did not complete any of the questionnaires (n = 6) or
"wanted to participate but could not come" (n = 5). In
total 71 patients (mean age 38 years SD ± 13, range 19–
65) with a duration of IBS for 2 to 50 years were included.
All patients taken part in this process were at the time of
recruitment offered to take part in two research projects,
(LU-510-02 and LU 735-02), approved by the local Ethics
Committee of Lund University. They all reviewed andBMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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signed a written, informed consent, and completed the
three questionnaires; the VAS-IBS, the GSRS and the
PGWB. All questionnaires were sent to the patients by
mail, together with written information. The question-
naires were collected at the hospital when they were
signed up for one of the two research projects.
Questionnaires
The content validity index consisted of instructions and
31 questions about the VAS-IBS. Each expert panel mem-
ber graded the content relevance, agreement of the defini-
tion of the item, and the relevance of the scale for each of
the nine items in the VAS-IBS [38], on a four point scale
(4 reflects total relevance and 1 indicates total irrele-
vance). The experts were also asked to give an opinion on
the application of the VAS-IBS, guided by four questions
in the end of the questionnaire. The content validity index
has been validated by experts in the field and evaluated
for face validity.
The GSRS is a Swedish disease-specific questionnaire
designed to evaluate gastrointestinal symptoms. It was
originally constructed as an interview-based rating scale
[39], and was later modified to become a self-adminis-
tered questionnaire [40,41]. The questionnaire includes
15 items divided into five dimensions; Abdominal Pain
Syndrome (3 items), Reflux Syndrome (2 items), Indiges-
tion Syndrome (4 items), Diarrhoea Syndrome (3 items),
and Constipation Syndrome (3 items). Each item is eval-
uated on a seven-grade Likert scale and gives a total range-
value between 15 and 105, i.e. the higher the scores, the
more pronounced are the symptoms.
The PGWB is a generic questionnaire to be used to meas-
ure positive and negative aspects of psychological well-
being and distress [42]. The questionnaire includes 22
items divided into six dimensions: Anxiety (5 items),
Depressed mood (3 items), Positive well-being (4 items),
Self-control (3 items), General health (3 items) and Vital-
ity (4 items). A six-grade Likert scale is used to measure the
items, which gives a total range-value between 22 and
132, i.e. the higher the value, the better is the patient's psy-
chological well-being.
The GSRS and the PGWB have been used on Swedish
patients with functional bowel disorders [36,43], and
norm values for healthy controls have been described
[35].
Psychometric characteristics
VAS-IBS was psychometrically tested to study whether it
measured the construct of interest, and how the question-
naire behaved in relation to a variety of conditions. All
statistical analyses were carried out by SPSS 11.0 for Win-
dows®. A p value <0.05 was considered statistically signif-
icant.
Content validity
There are no statistical tests or other objective methods
available to prove how adequately the sample of ques-
tions reflects the purpose of a measurement, but face
validity considered by one or several experts can be used
[15,38]. The content validity of the VAS-IBS was the meth-
odological judgement made by experts in the content
area, and they completed a content validity index. The
level of agreement was set to no more than one expert
panel member scoring an item less than 3 on a four-point
scale [44].
Criterion validity
The concurrent validity was the approach chosen to estab-
lish the criterion validity of the VAS-IBS. It was measured
by a calculation of the relation between the items related
to physical symptoms in the VAS-IBS and the GSRS as well
as between the item concerning mental health in the VAS-
IBS and the total sum of the PGWB. The item concerning
Abdominal Pain was compared to the dimension Abdomi-
nal Pain (GSRS), the item concerning Diarrhoea to the
dimension Diarrhoea (GSRS), the item concerning Consti-
pation  to the dimension Constipation (GSRS), and the
item concerning Bloating and Flatulence to the dimension
Indigestion (GSRS). The item concerning Vomiting and
Nausea was compared to only one of the two items in the
dimension Reflux (GSRS), since the other item was about
heartburn. The relationships were described by calculat-
ing a correlation coefficient by the Pearson's correlation
test. A correlation coefficient range from +1.00 for a per-
fect and positive correlation to 0.0 for no correlation at all,
to -1.00 for a perfect negative correlation [15].
Item reduction
Before an item was removed on the basis of the comments
of the expert panel, the clinical importance and relevance
of the item were judged. Pearson's correlation test was
used to assess the correlation between all the items in the
VAS-IBS [15,45]. In present study items that had a high
correlation (>0.80) were considered for removal, as well
as items that had >5 percent missing data.
Test-retest reliability
The test-retest reliability was performed on the first ver-
sion of the VAS-IBS, and a reasonable intra-class correla-
tion coefficient value is according to Streiner and Norman
[15] about 0.70. Expert opinions regarding the appropri-
ate interval vary from an hour to a year depending of the
situation, but two weeks are normal [15]. In this study the
time interval was set to four weeks, before the patients
were included in other in other research projects.BMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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Acceptability of the scale
Concerning the relevance of the scale, the comments of
the expert panel were taken into account. The scale score
distribution was considered from four aspects; score span,
mean score, scale floor and ceiling effects, and scale skewness.
The scale was considered acceptable when observed scores
were well distributed and the mean scores were near the
midpoint of the scale [14]. There are no generally accepted
criteria for floor and ceiling effects and the limits in this
study was set at 20 percent or less [14]. The skewness sta-
tistics were acceptable between -1 and + 1 [14].
Internal consistency reliability
Taken into account that IBS can be explained as a biopsy-
chosocial model [3], the VAS-IBS should be regarded as a
one-dimensional questionnaire, despite that the items
included are related to several health aspects. Alpha-if-
item deleted was used to assess the degree of consistency
or homogeneity of the items in the final version of the
VAS-IBS, after item reduction. The higher the value, the
more reliable is a measuring instrument. A minimum
coefficient of 0.70 was required for the Cronbach's alpha
internal consistency reliability coefficient for the items,
but not higher than 0.90 [15,45].
Other aspects
The simplicity and the speed with which the VAS-IBS was
completed were also taken into consideration as well as
number of internal missing data.
Results
Content validity
The expert panel agreed that the VAS-IBS gives a good pic-
ture of how a patient with IBS might feel, and all members
except one thought that the VAS-IBS might be useful in
clinical practice. Agreement was achieved for all items
concerning the relevance, as well as the definitions of all
items. One item (quality of life) achieved total consensus
concerning its relevance (all experts scored 4). The results
of the experts' agreement can be seen in Table 2. However,
some members of the panel suggested the inclusion of
additional items. One expert suggested that items related
to the sensation of incomplete evacuation and the urgency to
defecation should be added. Another expert suggested add-
ing an item related to the patient's daily life and a third sug-
gested that an item about food intolerance might be of
value. One expert suggested that the patient's definition of
each symptom should be registered in the questionnaire,
but did not give any advice on how this should be done.
Criterion validity
The calculations were performed by using Pearson's corre-
lation test, and all 71 completed VAS-IBS questionnaires
were used for this calculation. All correlations were statis-
tically significant (p < 0.0001) and in the expected direc-
tions (Table 3).
Item reduction
The item Vomiting and Nausea was suggested to be
removed by one of the expert panel members. This item
was according to the scale score distribution, beyond the
limits set in this study. However, this item should remain,
since Vomiting and Nausea is common in patients with IBS
[39], especially among women [33]. In the present 37 per-
cent of the women scored 50 or less on this item, indicat-
ing that symptoms were present.
Four of the expert panel members suggested that the item
Overall bowel symptoms could be excluded, which was also
the intension, since the item was used only as a control
item. There were correlations between the item Overall
bowel symptoms and the items concerning the individual's
Table 2: The expert panel members' (n = 9) agreement on the items in the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-
IBS) concerning content validity (relevance and definition) and acceptability of the scale.
Relevance Definition Acceptability of the scale
Score 4 and 3 Score 2 and 1 Score 4 and 3 Score 2 and 1 Score 4 and 3 Score 2 and 1
Physical symptoms
Overall item bowel symptoms 8 (6+2) 1 8 (4+4) 1 9 (8+1) 0
Abdominal Pain 9 (8+1) 0 9 (6+3) 0 8 (6+2) 1
Diarrhoea 9 (8+1) 0 8 (6+2) 1 8 (6+2) 1
Constipation 9 (8+1) 0 8 (6+2) 1 8 (6+2) 1
Bloating and Flatulence 8 (7+1) 1 8 (6+2) 1 9 (7+2) 0
Vomiting and Nausea 8 (6+2) 1 8 (5+3) 1 8 (7+1) 1
Mental health
Perception of mental well-being 9 (6+3) 0 9 (6+3) 0 9 (9+0) 0
Quality of Life
Well-being previous week 9 (8+1) 0 9 (6+3) 0 9 (9+0) 0
Perception of quality of life 9 (9+0) 0 9 (8+1) 0 9 (9+0) 0
The level of agreement was set to no more than one panel member scoring an item at less than 3.BMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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bowel symptoms; Abdominal Pain (r = 0.659, p < 0.0001),
Diarrhoea (r = 0.286, p < 0.034), Bloating and Flatulence (r
= 0.457, p < 0.0001), and Vomiting and Nausea (r = 0.284,
p < 0.036). However, there was no correlation between the
overall question and the item concerning Constipation (r =
0.232, p < 0.089). There was no correlation above 0.80, as
required limit for removal, between any of the items in
the VAS-IBS. However, there was a strong correlation
between the item Well-being during previous week and the
item Perception of quality of life (r = 0.762, p < 0.0001), and
two experts also suggested that one of these items could be
removed. To avoid misunderstanding of the sentence of
the words "wellbeing" and "quality of life", these two
items were replaced with the item "How much/little have
your gastrointestinal problems influenced your daily life?".
The internal validity in the VAS-IBS was high, since all
items in the VAS-IBS questionnaires, which were handed
in, were completed, and no data were missing. In total
four items in the GSRS and the PGWB were left unan-
swered and they were replaced by the mean value of the
dimension.
Test-retest reliability
The test-retest reliability of the first version of the VAS-IBS
had intra-class correlation coefficients ranging from 0.40
(Vomiting and Nausea) to 0.80 (Constipation). The test-
retest showed acceptable values above 0.70 for each item
except for Vomiting and Nausea and Bloating and Flatulence
(0.63). There were no significant differences in scores
between the first and second administrations.
Acceptability of the scale
Agreement was achieved in the expert panel concerning
the choice of the VAS as a preferable scale (Table 2). All
items in the final version of the VAS-IBS except one, the
item concerning Daily life (0–80), spanned the full range
of the scale (0–100). The mean scores were situated near
the midpoint of the scale (40–60) for all items except two
namely; the item concerning Bloating and Flatulence
(33.3), and the item concerning Vomiting and Nausea
(66.1) (Table 4). The items' floor effects were low and
ranged from 2.8 to 18.8 %. The ceiling effects range from
0 to 25.4 %, but only the item concerning Vomiting and
Nausea was above the limit of 20 % set for this study
(Table 4). All scale scores were in the acceptable range for
skewness (Table 4).
Internal consistency reliability
The psychometric testing of the final version of the VAS-
IBS, based on 16 questionnaires, confirmed that the VAS-
IBS is an acceptable, homogeneous, patient-reported
Table 4: The score range, mean as well as floor and ceiling effects and skewness of each item in the final version of the Visual Analogue 
Scale for Irritable Bowel Syndrome (VAS-IBS), as scored by the participating women (n = 71).
VAS-IBS Score Range* Mean (SD) Floor effects % Ceiling effects % Skewness
Physical symptoms
Abdominal Pain 0–100 46.5 (29.4) 4.2 7.0 0.444
Diarrhoea 0–100 60.0 (34.3) 7.1 20.0 -0.283
Constipation 0–100 58.8 (32.9) 2.8 12.7 -0.226
Bloating and Flatulence 0–100 33.3 (27.1) 8.5 1.4 0.774
Vomiting and Nausea 0–100 66.1 (33.8) 4.2 25.4 -0.543
Mental health
Perception of mental well-being 0–100 53.2 (30.0) 5.5 5.6 -0.044
Quality of Life
Influence daily life ** 0–80 43.6 (29.2) 18.8 0 -0.297
The limit of the floor and ceiling effect was set at 20% or less and the skewness should be between -1 and +1 to be acceptable. 0 = worst symptom/
health and 100 = best symptom/health
** n = 16
Table 3: Criterion validity (Pearson's correlation test) between the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) and 
the Gastrointestinal Symptom Rating Scale (GSRS) as well as the Psychological General Well Being Index (PGWB) (n = 71).
VAS-IBS GSRS- Pain GSRS- 
Diarrhoea
GSRS- 
Constipation
GSRS- Indigestion GSRS- item 
Vomiting/nausea
PGWB
Physical symptom
Abdominal Pain -0.597
Diarrhoea -0.806
Constipation -0.770
Bloating and Flatulence -0.664
Vomiting and Nausea -0.814
Mental health
Perception of mental well-being 0.689
Values are given as correlation coefficients and are all statistically significant, p < 0.0001.BMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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questionnaire with internal consistency reliability. The
overall VAS-IBS showed a high degree of internal consist-
ency reliability as indicated by Cronbach's alpha internal
consistency reliability coefficient, with a value of 0.85
(>0.70 required). As can be seen in Table 5 all the seven
items performed well together as a composite measure.
Each of the items had a high alpha value (0.81–0.85) if
item was deleted.
Other aspects
It took only a few minutes to calculate the scores in each
VAS-IBS questionnaire and no manual was needed. The
scores of each line were measured by a hand-held ruler. A
conclusion based on the scores was easily reached and just
by looking at the marks on the line, made by the patient,
the health care professional could form an opinion of the
patient's main complaints. The patients thought it was
easy to complete the VAS-IBS and they were pleased that
the questionnaire did not include more items.
Discussion
The psychometric testing confirms that the VAS-IBS is an
acceptable, homogeneous, patient-reported questionnaire
with content and criterion validity and internal consist-
ency reliability. The items in the VAS-IBS capture the main
physical concerns women with IBS might present,
although the expert panel suggested some changes.
According to one panel member items related to sensation
of incomplete evacuation and to urgency to defecation, could
be added to the questionnaire. Sensation of incomplete evac-
uation was included in the first criterion for IBS [46], but
was later transferred to the list of symptoms that cumula-
tively support the diagnosis of IBS [46]. After careful con-
sideration, items on these issues could be added to the
VAS-IBS as "yes" or "no" questions as a reminder of issues
which should be discussed at the consultation. The result
of these dialogues should be added to the patients' medi-
cal record. One panel member suggested adding an item
about food intolerance, which is a good point, but the pur-
pose of the VAS-IBS is to evaluate symptoms and not to
discover reasons for the patients' symptoms. Food intoler-
ance is a separate and complicated issue, and not a part of
IBS. The item Vomiting and Nausea was suggested to be
removed by one of the expert panel members, but should
remain, since Vomiting and Nausea is common in patients
with IBS [39], especially among women [10,33]. This item
was according to the scale score distribution, beyond the
limit for ceiling effect set in this study. However, since not
all patients having IBS suffers from this symptom, this is
an expected result.
In the present study, the time window for each item was
set to the previous week in order to correlate with the time
window in the GSRS and the PGWB. However, a longer
period might be preferable to use in clinical practice, since
it sometimes takes time before an improvement of a treat-
ment can be achieved. As a suggestion, one month might
be preferable, but it depends on the circumstances under
which the VAS-IBS is to be used. Further testing of differ-
ent time intervals is needed.
To choose VAS as the scaling method for the scoring of the
items seems to be a correct choice. The items discrimi-
nated well between individuals according to the scale
score distribution, and the mean agreement of the expert
panel concerning the scale was also high. However, the
items have not been weighted against each other, since the
purpose was to create a questionnaire to follow each of
the patient's complaints over time, and the individual
items in the VAS-IBS should not be combined into sub-
scales of each concept or be calculated into a total score.
The patients participating did not report any difficulties
when using the VAS, although such problems have been
reported [48]. The simplicity of using the questionnaire is
important to maintain a high adherence among patients
as well as among health care professionals. The question-
naire should not be a burden for them, but of assistance.
Table 5: The internal consistency of the final version of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) 
(Cronbach's alpha) (n = 16).
VAS-IBS Alpha-if-item deleted Cronbach's alpha coefficient
Physical symptoms
Abdominal Pain 0.83
Diarrhoea 0.85
Constipation 0.85
Bloating and Flatulence 0.83
Vomiting and Nausea 0.81
Mental health
Perception of mental well-being 0.81
Quality of Life
Interference with daily life 0.83
Overall scale 0.85
A minimum coefficient of 0.70 was requiredBMC Gastroenterology 2007, 7:16 http://www.biomedcentral.com/1471-230X/7/16
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To clarify for the patients, faces showing variations in their
expression of symptoms might be added at the ends of the
lines [49]. The purpose was to create a questionnaire to be
used by all health care professionals to compare the out-
come of different kinds of therapies in patients with estab-
lished IBS according to current guidelines [3,6]. It is a
strength that different health care professionals can use
the VAS-IBS to assess the patients' status over time, but it
might be a weakness that the questionnaire do not
include the diagnostic criteria for IBS. Items concerning
this issue were deliberately left out, since in Sweden only
physicians are allowed to establish the diagnosis. The
VAS-IBS should serve as a complement to the anamnesis
and measure the response to treatment of symptoms
related to IBS. However, symptoms, as for example diar-
rhoea and constipation, mean different things to different
people. This fact may have been affected the statistical
result concerning reliability, but in clinical practice this
matter should not be a problem, since patients always will
be compared to themselves over time.
There are limitations of this study and the stability of the
VAS-IBS is one of them. The intra-class correlation coffe-
cient for Bloating and Flatulence as well as for Vomiting
and Nausea was low in the first version of the VAS-IBS.
Patients' symptoms vary over time [47], especially bloat-
ing and nausea, and the results could be caused by the
long time interval (four weeks) for the test-retest, so a
shorter time window for that purpose had been prefera-
ble. The final version of the VAS-IBS needs to be further
tested by assessing the sensitivity to change in use in clin-
ical practice.
The capacity of the VAS-IBS to respond to treatments has
not been judged. It is a challenge to establish cut-off
points between statistical changes and those changes
which benefit the patient, and one of the major problems
is the lack of a definition of what should be accepted as a
clinical improvement of the patients' complaints. Patients
suffering from IBS are a heterogeneous group, and no bio-
logical makers are available to quantify the severity of IBS
or a change in severity, which makes the judgments more
difficult. However, a small degree on VAS could be clini-
cally meaningless, but this problem can appear in all
kinds of scales methods [15].
Also the selection of the patients in this study ought to be
discussed. It was difficult to recruit patients to take part in
the study, partly due to the treatment they had been given
during the years of their illness [50]. If the participants
had been taken better care of, they would also have been
more eager to play a part in the research projects. The high
number of patients' not participating in this study may be
a limitation. We only know the diagnosis, age and the rea-
son for refraining concerning the patients not included. It
is likely that the women who took part in the study were
especially interested, since all patients included, who were
asked to complete a questionnaire, fulfilled it. The VAS-
IBS has only been used for research and tested only on
Swedish women suffering from IBS, and needs therefore
to be used in clinical practise, at primary as well as at sec-
ondary care level, cross-culturally, in women as well as in
men before its clinical significance can be established.
Before the VAS-IBS can be used in other languishes than
Swedish, the VAS-IBS needs to be properly translated and
validated in the actual languish.
Parallel to the present study the GSRS-IBS was developed
[51] and evaluated on patients in the USA and the UK. The
idea was to construct a questionnaire which could be used
in clinical research. The GSRS-IBS is a short, user-friendly,
13-item questionnaire and a seven-point Likert scale is
used for each item. In the GSRS-IBS items sensation of
incomplete evacuation and  urgency to defecation are
included, but items concerning vomiting and/or nausea are
missing. Since the VAS-IBS and the GSRS-IBS include dif-
ferent items and use different scales, they could both be
useful in clinical practice. However, the VAS-IBS might be
preferable, since it has fewer items and requires few calcu-
lations.
Conclusion
The items in the VAS-IBS capture the main physical con-
cerns women with IBS might exhibit. The VAS-IBS is
designed to detect differences in five main complaints
related to bowel symptoms, mental health as well as daily
life, and is intended to be used in clinical practice as a
complement to the anamnesis. The VAS-IBS seems to be a
valid and reliable questionnaire and appears to be user-
friendly, for patients as well as for health professionals.
The questionnaire is easy to complete and unproblematic
to calculate. It is possible to quickly form an opinion of
the patients' complaints. As a result of the psychometric
testing the VAS-IBS could serve as a useful questionnaire
in different situations to quantify the impact that gastroin-
testinal symptoms may have on patients with IBS. How-
ever, the VAS-IBS has to be used in clinical practice and
further tested before the clinical significance can be estab-
lished. The time window is set to one month in the final
version of the VAS-IBS (Appendix 1), but further testing of
different time intervals is needed.
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Appendix 1
Visual Analogue Scale for Irritable Bowel Syndrome
(VAS-IBS)
How disturbing during the last month have your prob-
lems concerning your:
abdominal pain ?
diarrhoea?
constipation?
bloating and flatulence?
vomiting and nausea?
How do you rate your mental well-being over the past
month?
How much/little have your gastrointestinal problems
influenced your daily life over the past month?
Have you during the last month felt urgency to defeca-
tion? YES/NO
Have you during the last month felt that your bowel has
not
been completely empty after visiting the toilette? YES/NO
Bengtsson et al.
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